Lazertinib
- Generic Name
- Lazertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N8O3
- CAS Number
- 1903008-80-9
- Unique Ingredient Identifier
- 4A2Y23XK11
- Background
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 365
- Registration Number
- NCT06667076
- Locations
- πΊπΈ
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
πΊπΈProvidence Medical Foundation, Santa Rosa, California, United States
πΊπΈHope and Healing Cancer Services, Hinsdale, Illinois, United States
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 160
- Registration Number
- NCT06268210
- Locations
- π°π·
Severance hospital, Seoul, Korea, Republic of
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 120
- Registration Number
- NCT06156527
- Locations
- π°π·
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
π°π·AJOU university hospital, Suwon-si, Gyeunggi-do, Korea, Republic of
π°π·National Cancer Center, Goyang-si, Gyeunggi-do, Korea, Republic of
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT06120140
- Locations
- πΊπΈ
USC Norris Oncology Hematology Newport Beach, Newport Beach, California, United States
πΊπΈKaiser Permanente Oakland Medical Center, Oakland, California, United States
πΊπΈKaiser Permanente Roseville Medical Center, Roseville, California, United States
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT06106802
- Locations
- π°π·
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 129
- Registration Number
- NCT06020989
- Locations
- π°π·
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05896683
- Locations
- π§πͺ
SGS Belgium NV, Edegem, Belgium
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 534
- Registration Number
- NCT05862194
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT05742594
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
Impact of Lazertinib Dose Modification on Effectiveness and Safety
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05716672
- Locations
- π°π·
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
π°π·Kyungpook National University Hospital, Daegu, Korea, Republic of
π°π·Inje University Busan Paik Hospital, Busan, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.